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Aortic valveCalciﬁc aortic valve disease (CAVD) is a chronic inﬂammatory condition and affects a large number of elderly
people. Aortic valve interstitial cells (AVICs) occupy an important role in valvular calciﬁcation and CAVD
progression. While pro-inﬂammatory mechanisms are capable of inducing the osteogenic responses in AVICs,
the molecular interaction between pro-inﬂammatory and pro-osteogenic mechanisms remains poorly under-
stood. This study tested the hypothesis that intercellular adhesionmolecule-1 (ICAM-1) plays a role inmediating
pro-osteogenic factor expression in human AVICs. AVICs were isolated from normal human aortic valves and
cultured in M199 medium. Treatment with leukocyte function-associated factor-1 (LFA-1, an ICAM-1 ligand)
up-regulated the expression of bone morphogenetic protein-2 (BMP-2) and resulted in increased alkaline phos-
phatase activity and formation of calciﬁcation nodules. Pre-treatment with lipopolysaccharide (LPS, 0.05 μg/ml)
increased ICAM-1 levels on cell surfaces and exaggerated the pro-osteogenic response to LFA-1, and neutraliza-
tion of ICAM-1 suppressed this response. Further, ligation of ICAM-1 by antibody cross-linking also up-regulated
BMP-2 expression. Interestingly, LFA-1 elicited Notch1 cleavage and NF-κB activation. Inhibition of NF-κB
markedly reduced LFA-1-induced BMP-2 expression, and inhibition of Notch1 cleavage with a γ-secretase
inhibitor suppressed LFA-1-induced NF-κB activation and BMP-2 expression. Ligation of ICAM-1 on human
AVICs activates the Notch1 pathway. Notch1 up-regulates BMP-2 expression in human AVICs through activation
of NF-κB. The results demonstrate a novel role of ICAM-1 in translating a pro-inﬂammatory signal into a pro-
osteogenic response in human AVICs and suggest that ICAM-1 on the surfaces of AVICs contributes to the
mechanism of aortic valve calciﬁcation.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Calciﬁc aortic valve disease (CAVD) is one of the leading cardiovascu-
lar diseases with a prevalence of 1% to 2% in people over the age of
65 years [1]. Similar to atherosclerosis, CAVD is a chronic inﬂammatory
condition [2]. The “early lesions” associatedwith CAVD are characterized
by inﬂammatory changes, including the accumulation of T lymphocytes
and mononuclear cells in valvular tissue [3,4]. This is supported by the
observation that explanted aortic valves frompatientswith CAVDexhibit
abundant lymphocytes and macrophages. Aortic valve interstitial cells
(AVICs) have been demonstrated to play an important role in the valvu-
lar inﬂammatory and osteogenic responses [5,6]. A number of studies00 East 19th Avenue, Box C-320,
eng).indicate that bone morphogenetic protein-2 (BMP-2), a pro-osteogenic
protein, is involved in vascular and valvular calciﬁcation [1,6], and
several pro-inﬂammatory stimuli, including Toll-like receptor agonists,
are capable of inducing BMP-2 expression in human AVICs [7–9].
Further, stimulation of human AVICs with BMP-2 results in osteogenic
reprogramming [10]. Although leukocyte inﬁltration is evident in
diseased human aortic valves, it remains unknown whether the interac-
tion of inﬁltrated leukocyteswithAVICs has an impact onAVIC osteogenic
responses.
Bacterial products and pro-inﬂammatory cytokines evoke an osteo-
genic response in AVICs through Toll-like receptors or cytokine receptors
[7,8,11]. There could be unique pro-inﬂammatory factors that exert ef-
fects onAVIC osteogenic response via novel signaling pathways. Intercel-
lular adhesionmolecule (ICAM)-1may be one of such pro-inﬂammatory
factors. ICAM-1 is an immunoglobulin (Ig)-like cell adhesion molecule
constitutively expressed on cardiovascular cells [12]. Stimulation of
cells with pro-inﬂammatory factors, such as interleukin (IL)-1, tumor
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expression in a variety of cell types. ICAM-1 is involved in leukocyte
migration and adhesion in the sites of inﬂammation [13–16]. Therefore,
it interacts directly with integrins on leukocyte surfaces. Interestingly,
ICAM-1 is found to function as a receptor for leukocyte integrins to elicit
intracellular signaling in cells that interact with leukocytes [17,18].
Indeed, the β2 integrins on leukocytes, i.e. lymphocyte function-
associatedmolecule-1 (LFA-1, CD11a/CD18) andmacrophage-1 antigen
(MAC-1, CD11b/CD18), are found to be ligands for ICAM-1 on effector
cells and induce ICAM-1-dependent cellular activation in a variety of
effector cells, such as vascular endothelial cells [19–21].
The physiologic outcome of engagement of ICAM-1 by β2 integrins
and the resultant cell activation depend, in part, upon the type of cells.
Activation of ICAM-1 on endothelial cells might elicit increased produc-
tion of cytokines, such as IL-8 and RANTES, or increased expression of
adhesion molecules (including ICAM-1 and VCAM), leading to en-
hanced leukocyte trafﬁcking [22]. Human AVICs express high levels of
ICAM-1 in response to pro-inﬂammatory stimulation [7,23]. Elevated
ICAM-1 expression by AVICs should play a critical role in mediating
leukocyte inﬁltration to valvular tissue. It remains unknown, however,
whether ligation of ICAM-1 on AVICs has an effect on cellular osteogenic
response.
We hypothesize that ICAM-1 on cell surfaces of human AVICs mod-
ulates cellular osteogenic response. The purposes of this study were to
determine the effect of ICAM-1 ligation on the expression of BMP-2 in
human AVICs and to elucidate the signaling mechanism that mediates
the effect.
2. Materials and methods
2.1. Materials
CD11a (LFA-1) peptide was purchased from Abcam, Inc. (Cambridge,
MA). Monoclonal antibody against human ICAM-1 was purchased from
Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Polyclonal ICAM-1-
neutralizing antibody was purchased from EMD Chemicals, Inc. (San
Diego, CA). PE-conjugated human ICAM-1 antibody was purchased
from eBioscience, Inc. (San Diego, CA). Antibodies against Notch1,
NICD1, β-actin, phosphorylated NF-κB p65 and total NF-κB p65 were
purchased from Cell Signaling, Inc. (Beverly, MA). The antibody against
phosphorylated NF-κB p65 identiﬁes the phosphorylation of Ser536.
Antibody against BMP-2 was purchased from Prosci, Inc. (Poway, CA).
Medium 199 was purchased from Lonza (Walkersville, MD). Recombi-
nant Jagged1 and BMP-2 ELISA kit were purchased from R&D System
(Minneapolis, MN). Jagged1 ELISA kit was purchased from Uscn Life Sci-
ence Inc. (Germany). Kit for NF-κB DNA-binding assay was purchased
from Active Motif (Carlsbad, CA). Cell lysis buffer was purchased from
Thermo Fisher Scientiﬁc (Rockford, IL). LPS (E. coli 0111:B4) and all
other chemicals and reagents were purchased from Sigma-Aldrich
Chemical Co (St Louis, MO).
2.2. Cell isolation and treatment
Normal aortic valve leaﬂets were collected from the explanted
hearts of 6 patients undergoing heart transplantation (4 males and 2
females, mean age 61 ± 7.2 years). All patients gave written consent
for the use of their heart valves for this study. This study was approved
by the Institutional Review Board of the University of Colorado Denver.
AVICs were isolated from each of the aortic valve leaﬂets, and indi-
vidual isolate was cultured using a previously described method [7].
Brieﬂy, valve leaﬂets were subjected to sequential digestionswith colla-
genase to eliminate endothelial cells and release interstitial cells, and
then interstitial cells were collected by centrifugation. Interstitial cells
were cultured inM199 growthmedium containing penicillin G, strepto-
mycin, amphotericin B and 10% fetal bovine serum. When cell culture
reached 80 to 90% conﬂuence, cells were subcultured on plates andchamber slides for the experiments. Cells from passages 4 to 6 were
used for this study.
Cells were stimulated with LPS (0.05 μg/ml) for 1 to 8 h to up-
regulate the levels of ICAM-1 on cell surfaces. Cells were treated with
LFA-1 for 24 h, with or without prior to stimulation with LPS, to assess
the effect of this ICAM-1 ligand on BMP-2 expression. To determine
the role of ICAM-1 in the effect of LFA-1, cells were treated with
ICAM-1-neutralizing antibody (10 μg/ml) prior to LFA-1 treatment.
Ligation of ICAM-1 by antibody cross-linking was performed to con-
ﬁrm the role of ICAM-1 in the induction of BMP-2 expression, using the
method described previously [24–27]. Brieﬂy, cells were incubatedwith
15 μg/ml of mouse monoclonal antibody against human ICAM-1 at
37 °C for 60 min, and control cells were incubated with 15 μg/ml of
isotype-matching mouse IgG. Following incubation, cells were washed
three times with medium and subsequently incubated with 50 μg/ml
of anti-mouse IgG for 24 h.
Cells were treated with LFA-1 for 2 to 8 h to assess the effect of
ICAM-1 ligation onNotch1 activation, Jagged1 release andNF-κB activa-
tion. Speciﬁc NF-κB inhibitor (SN50; 100 μmol/L) was added to culture
medium 30 min before the addition of LFA-1 to determine the role of
NF-κB in the induction of BMP-2 expression. To determine the role of
Notch1 in NF-κB phosphorylation and BMP-2 expression, γ-secretase
inhibitor DAPT (50 μmol/L) was added 30 min prior to addition of
LFA-1.
2.3. Immunoﬂuorescent staining
Immunoﬂuorescent staining was applied to character cell surface
ICAM-1 expression as described previously [28]. After permeabilization
with a methanol/acetone mixture, cells on chamber slides were ﬁxed in
4% paraformaldehyde, incubated with a rabbit polyclonal antibody
against human ICAM-1 overnight at 4 °C. After washing with PBS, cells
were incubatedwith Cy3-tagged secondary antibody against the primary
antibody (imaged on the red channel). Nuclei were stained with bis-
benzimide (4′,6-diamidino-2-phenylindole, imaged on the blue channel).
Microscopywas performedwith a Leica DMRXAdigitalmicroscope (Leica
Mikroskopie und Systeme GmbH, Wetzlar, Germany) equipped with
Slidebook software (I. I. I. Inc., Denver, CO).
2.4. Flow cytometry
For direct immunoﬂuorescence staining, untreated or LPS-treated
cells (2 × 106 cells/ml) were pre-incubated in 5% BSA to block non-
speciﬁc binding. The cells were washed twice with PBS containing 1%
BSA and 0.02% sodium azide, and then incubated with 10 μl of PE-
conjugated monoclonal antibody against ICAM-1 or PE-conjugated
non-immune IgG at 4 °C for 30 min, and analyzed by a ﬂow cytometer
(Beckman Coulter FC500, Becton Dickinson, Franklin Lakes, NJ, USA).
2.5. Immunoblotting
Immunoblotting was applied to analyze ICAM-1, BMP-2, NICD1,
β-actin, phosphorylated NF-κB p65 and total NF-κB p65. Cells were
lysed in a sample buffer (100 mM Tris-HCl, pH 6.8, 2% SDS, 0.02%
bromophenol blue and 10% glycerol). Protein samples were separated
on gradient (4–20%)minigels and transferred onto nitrocellulosemem-
branes (Bio-Rad Laboratories, Hercules, California). The membranes
were blockedwith 5% non-fat drymilk solution for 1 h at room temper-
ature. The blockedmembraneswere incubatedwith a primary antibody
against the protein of interest. After washingwith TPBS (PBS containing
0.05% Twen 20), the membranes were incubated with a peroxidase-
linked secondary antibody speciﬁc to the primary antibody. Following
further washes, membranes were treated with enhanced chemilumi-
nescence reagents. Then the membrane was exposed on X-ray ﬁlm.
Image J was used to assess band density.
AB
Fig. 1. LFA-1 induces BMP-2 expression in humanAVICs. A. AVICs of normal aortic valves are treatedwith LFA-1 (0.5 or 1.0 μg/ml) for 24 h. A representative immunoblot, gel densitometric
data and ELISA data show that treatment with LFA-1 increases BMP-2 levels in cell lysate and culture media. n= 6; *P b 0.05 vs. untreated controls (Ctrl). B. AVICs of normal aortic valves
are treatedwith LFA-1 (1.0 μg/ml) for 7 or 21 days. Representative images (size bar= 200 μm) show that treatment with LFA-1 for 7 days up-regulates alkaline phosphatase activity and
that treatment for 21 days in conditioningmedium causes calciﬁcation nodule formation. Quantitative data (n= 6) conﬁrms that treatment with LFA-1 for 21 days increases the levels of
calcium deposits. *P b 0.05 vs. control cells (Ctrl) cultured in the conditioning medium.
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NF-κB p65 DNA-binding activity in cell lysate was measured by an
assay kit according to the manufacturer's instructions. The kit contains
96-well plates to which oligonucleotides containing the NF-κB binding
site are immobilized. Activated NF-κB binds to the oligonucleotides
and is detected with a speciﬁc antibody. The amount of active NF-κB
was determined using a microplate reader.
2.7. ELISA for BMP-2 and Jagged1
Cell culture supernatants were collected. Levels of BMP-2 and
Jagged1 were determined using ELISA kits as described previously [28].
2.8. ALP activity staining
Histochemical staining for alkaline phosphatase activity was
performed as previously described [29]. Brieﬂy, cell monolayers
were washed with PBS and ﬁxed for 10 min in 4% paraformaldehyde,
followed by incubation at room temperature for 30minwith amixture of
0.1 mg/ml of naphthol AS-MX phosphate, 0.5% N,N-dimethylformamide,
2 mMMgCl2, and 0.6 mg/ml of fast blue BB salt in 0.1 M Tris–HCl, and
pH8.5. Excessive dye was removed by washing with PBS. ALP activity
staining was examined and photographed with a Nikon Eclipse TS100
microscope (Tokyo, Japan).
2.9. Alizarin red S staining
Alizarin red S staining for calcium deposits was performed as
described previously [8,29,30]. Brieﬂy, cell monolayers were washed
three times with PBS and ﬁxed for 10 min with 4% paraformaldehyde.
Fixed cells were incubated with 0.2% alizarin red S solution (pH 4.2)
for 30 min. Excessive dye was removed by washing with distilled
water. Alizarin red S staining was examined and photographed with
a Nikon Eclipse TS100 microscope (Tokyo, Japan). To quantitatively
analyze Alizarin red stain, Alizarin red S stains were bleached with
10% acetic acid at 85 °C and assessed spectrophotometrically at
450 nm [31].
2.10. Statistical analysis
Data are presented as mean ± standard error (SE). Comparisons
between groups were performed using StatView software (Abacus
Concepts, Calabasas, CA) with one-way analysis of variance (ANOVA)
with the post hoc Fisher test. A difference was considered signiﬁcant at
P ≤ 0.05. Signiﬁcant differences were conﬁrmed with Mann–Whitney
non-parametric test.
3. Results
3.1. Ligation of ICAM-1 with LFA-1 induces BMP-2 expression and
osteogenic reprogramming in human AVICs
To determine the effect of ICAM-1 ligand on BMP-2 expression, we
exposed AVICs of normal aortic valves to LFA-1 (0.5 or 1.0 μg/ml) for
24 h. As shown in Fig. 1A, treatment with LFA-1 resulted in a dose-
dependent increase in BMP-2 protein levels in cell lysate and culture
media. In cells exposed to 1.0 μg/ml of LFA-1, levels of cell associated
BMP-2 increased by 4 folds (P b 0.05).Fig. 2. Up-regulation of ICAM-1 levels augments the BMP-2 response to LFA-1. Human AVIC
immunoblot shows that cells exposed to LPS express ICAM-1 protein in a time-depende
that ICAM-1 accumulates over time on the surfaces of cells treated with LPS, and ﬂow cytom
LPS stimulation for 8 h. *P b 0.05 vs. untreated controls (Ctrl). C. A representative immunoblot, g
increases BMP-2 levels in cell lysate and culture media of cells pretreated with LPS for 8 h. n =Our previous studies demonstrate that BMP-2 is capable of inducing
osteogenic reprogramming in human AVICs, and this pro-osteogenic
factor mediates human AVIC osteogenic reprogramming evoked by
pro-inﬂammatory stimuli [8]. As ICAM-1 ligand LFA-1 up-regulates
BMP-2 production, we tested the hypothesis that prolonged treatment
with LFA-1 will result in osteogenic reprogramming (increased alkaline
phosphatase activity and greater vulnerability to form calciﬁcation
nodules) in human AVICs. As shown in Fig. 1B, treatment with LFA-1
(1.0 μg/ml) for 7 days increased the number of cells that are positive
for alkaline phosphatase activity staining. In addition, treatment of
with LFA-1 for 21 days resulted in the formation of calciﬁcation deposits
in human AVICs cultured in conditioning medium (growth medium
with 10 mmol/L β-glycerophosphate, 10 nmol/L vitamin D3 and
10 nmol/L dexamethasone).3.2. LFA-1 induces BMP-2 expression in human AVICs in an
ICAM-1-dependent fashion
Since BMP-2 plays an important role in vascular and valvular calciﬁ-
cation [8,32], our further experiments concentrated on the mechanism
by which LFA-1 induces BMP-2 expression.
We examinedwhether up-regulation of ICAM-1, using pretreatment
with a low concentration of LPS as a tool, enhances the effect of LFA-1 on
BMP-2 expression. As shown in Fig. 2A, treatmentwith a low concentra-
tion of LPS (0.05 μg/ml) increased ICAM-1 protein levels over time and
resulted in a maximal increase at 8 h. Immunoﬂuorescence images
show apparent cell surface ICAM-1 after treatment with LPS for 8 h
(Fig. 2B), and ﬂow cytometry data show that ICAM-1 are detectable
on cell surfaces in 60% of cells (Fig. 2B) at 8 h. The results in Fig. 2C
show that LFA-1 induces a greater increase in BMP-2 levels in cell lysate
and culture media if cells are pretreated with LPS for 8 h. Thus, up-
regulation of ICAM-1 levels on cell surfaces exaggerates the effect of
LFA-1 on BMP-2 expression. It appears that LFA-1 induces BMP-2 expres-
sion in human AVICs in an ICAM-1-dependent fashion. To conﬁrm this,
we examined whether blocking ICAM-1 with a neutralizing antibody
may abrogate the effect of LFA-1 on BMP-2 expression. As shown in
Fig. 3, blocking ICAM-1 abolished BMP-2 expression in cells treated
with LFA-1 alone and markedly reduced BMP-2 levels in cells treated
with LPS + LFA-1 while non-immune IgG had no effect. Thus, LFA-1 in-
duces BMP-2 expression through an ICAM-1-dependent mechanism.
As LPS alone can induce a slight increase in cellular BMP-2 levels
(Fig. 3), the remaining low levels of BMP-2 in cells received LPS pretreat-
ment before treatment with ICAM-1-neutralizing antibody and LFA-1
could be due to the ICAM-1 ligation-independent up-regulation of
BMP-2 by LPS.3.3. Ligation of ICAM-1 by antibody cross-linking also induces BMP-2
expression in human AVICs
To further validate that ICAM-1 ligation induces BMP-2 expression in
humanAVICs,we treated cellswith cross-linking antibodies (monoclonal
anti-CAM-1 followed by a secondary antibody) for 24 h and analyzed
BMP-2 levels with immunoblotting. We found that ICAM-1 ligation
with antibody cross-linking induces BMP-2 expression, especially in
cells pretreated with LPS (Fig. 4). The results conﬁrmed that ligation of
ICAM-1 by different mechanisms up-regulates BMP-2 expression in
human AVICs.s are treated with a low concentration of LPS (50 ng/ml) for 1–8 h. A. A representative
nt fashion. B. Representative immunoﬂuorescence images (size bar = 20 μm) show
etry data (n = 6) show increased numbers of cells with ICAM-1 on their surfaces after
el densitometric data and ELISAdata show that treatmentwith LFA-1 (1.0 μg/ml)markedly
6; *P b 0.05 vs. untreated controls (Ctrl); #P b 0.05 vs. LFA-1 alone.
Fig. 3.Neutralization of ICAM-1 reduces the pro-osteogenic effect of LFA-1. Human AVICs
are treated with ICAM-1-neutralizing antibody (10 μg/ml) for 1 h prior to treatment with
LFA-1 (1.0 μg/ml). A representative immunoblot and densitometric data (n = 6) show
that treatment with ICAM-1-neutralizing antibody reduces BMP-2 expression induced by
LFA-1 or LFA-1 plus LPS pretreatment. *P b 0.05 vs. untreated controls (Ctrl); #P b 0.05 vs.
LFA alone; †P b 0.05 vs. LFA + IgG; ‡P b 0.05 vs. LPS + LFA and LPS + IgG + LFA.
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ICAM-1 ligation
It has been reported that ligation of ICAM-1 on endothelial cells can
activate NF-κB [26]. We determined whether NF-κB plays a role in
mediating the induction of BMP-2 expression by ICAM-1 ligation.
We examined NF-κB p65 phosphorylation in cells pretreated with
LPS and then exposed to LFA-1 for 2 to 8 h. The low dose of LPS applied
in this study induced detectable NF-κB p65 phosphorylation only at 2 h.
Interestingly, NF-κB p65 phosphorylation was observed at 4 and 8 h
after the exposure to LFA-1 (Fig. 5A). NF-κB DNA-binding activity was
also increased at 4 and 8 h after the exposure to LFA-1 (Fig. 5B).
To evaluate the role of NF-κB in BMP-2 expression induced by ICAM-
1 ligation, we treated cells with the speciﬁc NF-κB inhibitor SN-50
(100 μg/ml) or control reagent SN-50M prior to exposure to LFA-1.Fig. 4. ICAM-1 ligation by antibody cross-linking also induces BMP-2 expression. Human
AVICs with LPS pretreatment were incubated with 15 μg/ml of monoclonal anti-ICAM-1
or isotype-matching non-immune mouse IgG for 60 min and subsequently incubated
with 50 μg/ml of anti-mouse IgG for 24 h. A representative immunoblot and densitometric
data (n = 6) show that cross-linking of ICAM-1 with antibodies up-regulates the
expression of BMP-2. *P b 0.05 vs. untreated controls (Ctrl); #P b 0.05 vs. LPS alone
and LPS+ non-immune IgG, †P b 0.05 vs. cross-linking antibodies (Ab) in the absence
of LPS pretreatment.Results in Fig. 5C show that the NF-κB inhibitor SN50 reduces BMP-2
levels in cells exposed to LFA-1 alone or LPS + LFA-1. In contrast, the
control reagent SN50M had no effect. To conﬁrm the role of NF-κB, we
applied BAY 11-7082, a speciﬁc IKK inhibitor, and observed that inhibi-
tion of NF-κB activation with BAY 11-7082 also reduces BMP-2 levels in
cells exposed to LFA-1 alone or LPS + LFA-1 (Fig. 5C).
Together these results show that NF-κB activation occurs in human
AVICs in response to ICAM-1 ligation and that NF-κB plays an important
role in mediating BMP-2 expression induced by ICAM-1 ligation.
3.5. Notch1 has an essential role in BMP-2 expression induced by ICAM-1
ligation
We have observed that Notch1 modulates NF-κB activation in
human AVICs [23]. In the present study, we treated cells with LFA-1
for 4 or 8 h to examinewhether ICAM-1 ligation induces Notch1 activa-
tion in human AVICs. Notch1 intracellular domain (NICD1) generation
was analyzed with immunoblotting, and cellular release of Notch1
ligand Jagged1 was examined by ELISA. We found that the low dose of
LPS applied increases cellular levels of NICD1 slightly at 4 and 8 h. How-
ever, greater levels of NICD1 were observed in LPS-pretreated cells
exposed to LFA-1 for 4 or 8 h (Fig. 6A). Further, we found that ICAM-1
ligation with LFA-1 caused the release of Jagged1. Jagged1 levels in cul-
turemedia examined at 4 and 8 hwere signiﬁcantly elevated, especially
in cells pretreated with LPS (Fig. 6B). Therefore, Notch1 activation
induced by ICAM-1 ligation is associated with the secretion of Notch1
ligand Jagged1.
Notch1 is cleaved by γ-secretase to become active [33]. To deter-
mine the role of Notch1 activation in BMP-2 expression induced by
ICAM-1 ligation, we applied DAPT, a speciﬁc γ-secretase inhibitor, to
cells before LFA-1 treatment. Surprisingly, we found that treatment
with DAPT reduced BMP-2 expression induced by LFA-1 alone or
LPS + LFA-1 (Fig. 6C). It appears that the Notch1 pathway is required
for the induction of BMP-2 expression by ICAM-1 ligation.
To understand whether activation of Notch1 modulates NF-κB
activation, we examine the effect of DAPT treatment on NF-κB p65
phosphorylation and DNA-binding activity. The results in Fig. 6D show
that the levels of NF-κB p65 phosphorylation and DNA-binding activity
were markedly reduced by DAPT at 4 and 8 h in cells treated with
LPS + LFA-1. Together, our results demonstrate that activation of
Notch1 contributes to the mechanism underlying NF-κB activation
and the NF-κB-mediated up-regulation of BMP-2 expression induced
by ICAM-1 ligation.
4. Discussion
CAVD is a chronic inﬂammatory condition, and nodular calciﬁcation
of the aortic valve leaﬂets is a signiﬁcant manifestation of this disease
[34]. Progressive aortic valve calciﬁcation results in the restriction of
valvular opening and closing. Secondary left ventricular hypertrophy
drives the development of heart failure. Currently, aortic valve replace-
ment is the only available therapy. Understanding of the mechanism
responsible for aortic valve calciﬁcation is important for identiﬁcation
of targets for pharmacological intervention.
AVICs are known to play an important role in valvular calciﬁcation
andCAVDprogression. In addition, AVICs are believed to have the ability
to convert pro-inﬂammatory signals to a pro-osteogenic response.
While pro-inﬂammatory mechanisms are capable of inducing the oste-
ogenic responses in human AVICs, the molecular interaction between
pro-inﬂammatory and pro-osteogenic mechanisms remains poorly
understood. In the present study, we found that ligation of ICAM-1 on
human AVICs by leukocyte β-integrin LFA-1 induces the expression
and secretion of pro-osteogenic factor BMP-2 and that prolonged treat-
mentwith LFA-1 leads to AVIC osteogenic reprogramming (with elevated
alkaline phosphatase activity and a greater vulnerability to form calciﬁca-
tion deposits). It is known that secreted BMP-2 bind to its receptor in
AB
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Fig. 5. The NF-κB pathway mediates BMP-2 expression induced by ICAM-1 ligation. A. A
representative immunoblot and densitometric data (n = 6) show that LFA-1 (1.0 μg/ml)
induces NF-κB p65 phosphorylation in human AVICs pretreated with LPS. B. NF-κB
DNA-binding assay conﬁrms that LFA-1 increases NF-κB activity in LPS-pretreated cells.
C. Representative immunoblots and densitometric data (n = 6) show that inhibition of
NF-κB with SN50 or BAY 11-7082 suppresses BMP-2 expression induced by LFA-1 or
LPS + LFA-1. *P b 0.05 vs. untreated controls (Ctrl); #P b 0.05 vs. LPS alone at the same
time-point; †P b 0.05 vs. corresponding treatment + SN50M or DMSO.
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factor plays an important role in vascular and valvular calciﬁcation [8,32].
In the present study, we provided several lines of evidence to show that a
Notch1-NF-κB axis plays a critical role in mediating the up-regulation of
BMP-2 expression by ICAM-1 ligation in human AVICs. The results of
this study support a novel concept that ICAM-1 senses an inﬂammatory
signal to elaborate a pro-osteogenic response in human AVICs. This
study highlights the potential role of ICAM-1 in mediating aortic valve
calciﬁcation in an inﬂammatory milieu.4.1. Ligation of ICAM-1 is potent to induce the expression of BMP-2 in
human AVICs
Several reports have demonstrated thepresence of leukocytes in dis-
eased aortic valves, suggesting that an active inﬂammatory process is
involved in the development and/or progression of CAVD [1,3,4,35].
ICAM-1, the most extensively studied adhesion molecular of the ﬁve
ICAM molecules, acts as an important portal of entry for inﬂammatory
cell inﬁltration, and inﬁltrated monocytes and lymphocytes are known
to exaggerate tissue inﬂammation [36]. Currently, few studies have
examined ICAM-1 expression in AVICs [7,23]. Further, the impact of
the interaction between leukocyte integrins and ICAM-1 on AVIC
function is unknown.
LFA-1, a member of the β2-integrin family, is a potent ligand on the
surfaces of leukocytes andmediates leukocyte adhesion through binding
to ICAM-1 [37]. LFA-1 has αL- and β2-subunits, which are designated
as CD11a and CD18, respectively. The αL-subunit of LFA-1 contains an
I- (insert) domain that is essential for binding to ICAM-1 [38]. In this
study we choose CD11a as a representative of LFA-1. It is well described
that ligation of ICAM-1 by CD11a or LFA-1 is important for granulocyte
extravasation, lymphocyte-mediated cytotoxicity and the development
of speciﬁc leukocyte-mediated immunological responses [39].
The results of this study show that CD11a induces BMP-2 expression
in human AVICs via ligation of ICAM-1. Three lines of evidence support
this notion. First, up-regulation of cell surface ICAM-1 levels by LPS pre-
treatment augments the BMP-2 response to CD11a. Second, blockade of
ICAM-1using a neutralizing antibodyprior to LFA-1 treatment abolishes
the pro-osteogenic effect of CD11a. Lastly, we applied antibody cross-
linking as a tool for ICAM-1 ligation and observed that this approach
also up-regulates BMP-2 expression in human AVICs. Previous studies
have shown that cross-linking of ICAM-1 with antibodies activates en-
dothelial cells andmimics ligand/receptor interactions [20]. The present
study reveals a novel role of ICAM-1 in human AVICs. In view of the fact
that calciﬁc aortic valve disease is a chronic inﬂammatory condition and
involves valvular calciﬁcation, it is reasonable to postulate that ICAM-1
may function as a receptor in humanAVICs that senses an inﬂammatory
milieu and signals for the osteogenic response.
It should be noted that LPS induces the expression of multiple pro-
inﬂammatory mediators in human AVICs [7,23], and some of these
mediators may also contribute to the augmented BMP-2 expression
observed in cells treated with LPS plus LFA-1. Indeed, TNF-α has been
shown to induce BMP-2 expression in human AVICs [11]. However,
we observed in a previous study that LPS at a higher concentration
(200 ng/ml) fails to induce TNF-α in human AVICs [7]. Thus, TNF-α is
unlikely to be an important factor in the robust BMP-2 expression in-
duced by LPS plus LFA-1. Since ICAM-1-neutralization greatly reduces,
but not abrogates, BMP-2 expression in cells exposed to LPS plus LFA-1,
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and should be investigated in future studies.
4.2. The Notch1-NF-κB pathway is required for the induction of BMP-2
expression by ICAM-1 ligation in human AVICs
In the present study, we conﬁrmed that ICAM-1 ligation can up-
regulate NF-κB p65 phospholation and DNA-binding activity in human
AVICs. More importantly, our results indicate that NF-κB plays an im-
portant role inmediating the effect of ICAM-1 ligation on BMP-2 expres-
sion since treatment of cells with either of the two NF-κB inhibitors
applied (SN50 and BAY 11-7082) markedly suppresses BMP-2 expres-
sion following ICAM-1 ligation. Our previous studies on human AVICs
suggest that the NF-κB pathway is critical for BMP-2 expression [7,9].
The results of the present study show that ligation of ICAM-1 activates
this pathway to up-regulate BMP-2 expression.
It has been reported that ligation of ICAM-1 in endothelial cells acti-
vates PI3K that is linked to NF-κB [40]. However, human AVICs did not
exhibit such a change in PI3K activity (not shown). Surprisingly, we
found that ICAM-1 ligation causes Notch1 cleavage in human AVICs
that is associated with the release of Notch1 ligand Jagged1. Several
pro-inﬂammatory stimuli, particularly bacterial LPS, are found to acti-
vate Notch1 inmonocytes ormacrophages [41,42]. Our previous studies
found Notch1 activation in human AVICs exposed to LPS [9,23]. This is
the ﬁrst report that ligation of ICAM-1 induces Notch1 cleavage. Thus,
distinct pro-inﬂammatory signaling can lead to Notch1 activation in
human AVICs. It appears that ICAM-1 signaling activates Notch1 in
human AVICs via Jagged1 since ligation of ICAM-1 triggers the release
of this Notch1 ligand.
Notch1 activation involves its cleavage by γ-secretase to generate
the active segment NICD1, and we have found in a previous study that
γ-secretase inhibitor DAPT reduces NICD1 generation in human AVICs
[23]. To deﬁne the role of Notch1 activation in the pro-osteogenic re-
sponse to ICAM-1 ligation, we determined the effect of DAPT on BMP-
2 expression. Treatment with DAPT markedly reduces the production
of BMP-2 following ICAM-1 ligation. It is noteworthy that inhibition of
Notch1 and inhibition of NF-κB result in a comparable reduction in
BMP2 expression. It is possible that Notch1 activation and NF-κB activa-
tion are linear signaling events in human AVICs following ICAM-1 liga-
tion. In supporting this possibility, our previous work shows that
Notch1 ligand enhances TLR4-mediated NF-κB activation in human
AVICs [23]. We observed in the present study that inhibition of Notch1
activation with DAPT markedly reduces NF-κB activation in human
AVICs following ICAM-1 ligation, resulting in lower levels of BMP-2 ex-
pression. Thus, Notch1 appears to be upstreamof NF-κB in the induction
of BMP-2 expression although themechanismbywhichNICD1 activates
NF-κB remains unclear from the present study. Nevertheless, Notch1
plays a role in NF-κB-mediated BMP-2 response induced by ICAM-1
ligation.
Our previous study found that NICD1 interacts with IKK and modu-
lates TLR4-mediated NF-κB activation in human AVICs [23]. The results
of the present study indicate that Notch1 modulates NF-κB activation
induced by ICAM-1 ligation and thereby enhances BMP-2 expression.
The ﬁnding supports the notion that Notch1 signaling plays a role inFig. 6.Notch1plays a role inmediatingNF-κB activation and BMP-2 expression inducedby
ICAM-1 ligation. A. A representative immunoblot and densitometric data (n = 6) show
that LFA-1 (1.0 μg/ml) induces NICD1 generation in human AVICs pretreated with LPS.
*P b 0.05 vs. untreated controls (Ctrl); #P b 0.05 vs. LPS alone. B. ELISA data (n = 6)
show that LFA-1 (1.0 μg/ml) induces Jagged1 secretion in human AVICs with and without
LPS pretreatment. *P b 0.05 vs. untreated controls (Ctrl); #P b 0.05 vs. LFA-1 alone or
LPS alone. C. A representative immunoblot and densitometric data (n = 6) show that
inhibition of Notch1 with DAPT reduces BMP-2 expression induced by ICAM-1 ligation.
*P b 0.05 vs. vehicle controls; #P b 0.05 vs. corresponding treatment without DAPT. D. A
representative immunoblot, densitometric data and DNA-binding assay show that inhibi-
tion of Notch1with DAPTmarkedly reduces NF-κB p65 phosphorylation andDNA-binding
activity in cells exposed to LPS plus LFA-1. n= 6; *P b 0.05 vs. controls (Ctrl); #P b 0.05 vs.
LPS + LFA-1.
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Fig. 7. Schematic diagram depicting the mechanism underlying the induction of BMP-2 in
human AVICs by ICAM-1 ligation. The engagement of a ligand with ICAM-1 activates NF-
κB through Notch1-dependent and -independent mechanisms. Activated NF-κB initiates
BMP-2 expression to increase BMP-2 protein levels. A pre-exposure to LPS up-regulates
ICAM-1 levels on cell surfaces and augments ICAM-1-mediated BMP-2 response.
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and is consistent with the reports that show an important role of
Notch1 in vascular calciﬁcation. However, Notch is required for cardiac
and valvular development [43,44], and genetic Notch1 deﬁciency is
linked to aortic valve defects at birth and the development of calciﬁc
aortic valve disease [45]. In addition, several studies indicate that
Notch1 has an anti-osteogenic effect in the aortic valve. In this regard,
heterozygous Notch1 knockout in mice results in aortic valve calciﬁca-
tion [46], and prolonged inhibition of Notch1 in AVICs induces osteo-
genic gene expression [46–48]. It should be noted, however, that the
results of the present study and our previous ﬁndings [9] demonstrate
a role for Notch1 signaling in modulating NF-κB-mediated BMP-2
expression in human AVICs exposed to an inﬂammatory setting. Our
ﬁndings suggest that this signaling molecule plays differential roles in
different settings even though in the same tissue or cells.
5. Conclusion
In summary, the results of this study demonstrate that ligation of
ICAM-1 on human AVICs by leukocyte integrin LFA-1 induces BMP-2
expression via activation of the Notch1-NF-κB pathway (summarized
in Fig. 7). Speciﬁcally, ligation of ICAM-1 activates Notch1 to modulate
NF-κB activation and NF-κB-mediated BMP-2 expression. Thus, this
study demonstrates a novel role of ICAM-1 in translation of an inﬂam-
matory signal into a pro-osteogenic response in human AVICs and
suggests that ICAM-1 on the surfaces of AVICs may contribute to the
mechanism of aortic valve calciﬁcation in an inﬂammatory milieu.
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